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The role of vitamin C (ascorbate) in cancer prevention, tumor growth, and treatment is of
intense public interest. Clinical trial data have been sparse, contradictory, and highly contro-
versial, and robust pre-clinical data are required for progress.This paper reviews pre-clinical
models and their limitations with respect to ascorbate research. Most studies have utilized
animals able to synthesize ascorbate and thus are not ideal models of the human condition.
More recently, genetically modified mouse models have become available; yet, all studies
compared healthy and scorbutic mice.The majority of investigations to date concluded that
increased ascorbate led to decreased tumor growth, but data on mechanisms and doses
are inconclusive. Clinically relevant animal studies are still required to convince a generally
sceptical medical audience of the potential worth of ascorbate as an adjunct to therapy.
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INTRODUCTION
Vitamin C (ascorbate) is a small, water soluble molecule derived
from glucose. Although most animals synthesize ascorbate in their
liver or kidneys, it has become an essential vitamin for human
beings due to mutations in the terminal enzyme of its biosyn-
thesis pathway, l-gulonolactone oxidase (Gulo) (1, 2). Therefore,
human beings, together with other primates,guinea pigs, and some
fruit bats, require daily dietary ascorbate to maintain their health
and prevent their tissues becoming ascorbate deficient (scorbu-
tic). Although the extreme ascorbate deficiency condition, scurvy,
is rare, large proportions of the population are at risk of chronic
deficiency (3).
There are a myriad of roles attributed to ascorbate, with some
potentially important in cancer risk and progression,but most data
are derived from either cell-free or cell culture systems. Ascorbate
is a potent antioxidant believed to protect immune cells against
intracellular reactive oxygen species formed during the inflamma-
tory response (4). Ascorbate supports both the innate and adaptive
immune functions, inhibits excessive activation of the immune
system, and maintains natural neutrophil apoptosis, thus prevent-
ing tissue damage (5). It supports immune cell activity, especially
phagocytosis and T-cell function (4).
Ascorbate is a vital co-factor for a family of enzymes, the non-
heme and 2-oxoglutarate-dependent dioxygenases, which control
important cellular processes including hormone synthesis, pro-
tein structure, epigenetic changes, and response to low oxygen
(hypoxia) (6–10). Hypoxia is a characteristic of solid tumors, and
the extent of tumor hypoxia has been associated with more aggres-
sive cancers and poor patient outcome (11). Hypoxia-inducible
factor 1 (HIF-1) is the master regulator of cellular response to
Abbreviations: HIF-1, hypoxia-inducible factor 1; IP, intraperitoneal; IV, intra
venous; PO, per os (by mouth); SC, subcutaneous.
hypoxia, and HIF-1 levels and activity are under control of hydrox-
ylase enzymes that require ascorbate as a co-factor (9). Ascorbate
is essential for the development and maintenance of connective
tissues and wound healing, via the synthesis of collagen. Collagen
fibers form part of the extracellular matrix, a vital component of
solid tumors. In cell culture studies, collagen increased directional
migration of tumor cells, and introduction of ascorbate into the
media reduced this metastatic phenotype (12).
The functional role of ascorbate in cancer biology is complex
and remains unclear. Therefore, relevant animal models are crucial
for investigating its role during tumor growth and cancer therapy.
In contrast to cell culture systems, these in vivo models provide
a complex microenvironment, which contains the appropriate
physiological, immunological, and biomechanical components to
model heterogeneous tumor growth. This review will give an
overview of published data in animal models where the effect
of ascorbate on cancer was investigated. We have divided ani-
mal models into two broad categories: ascorbate-synthesizing or
ascorbate-dependent models.
ASCORBATE-SYNTHESIZING ANIMALS
Virtually all laboratory animals, including inbred wild type mice
and immune-deficient murine models, can synthesize their own
ascorbate.
WILD TYPE MICE WITH MURINE TUMORS
Inbred wild type mice (e.g., C57BL/6, BALB/c, and C3H) have been
used for >50 years to investigate tumor growth and treatment
response. These mice have a fully competent immune response,
which allows the study of the role of the immune system during
therapy, but require mouse-strain specific murine tumor mod-
els (syngeneic tumors). A pharmacokinetic study in C57BL/6
mice following either IV or IP injection (1 g/kg) of ascorbate
showed that plasma ascorbate can reach millimolar levels (13).
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Although IV administration resulted in an immediate increase in
plasma concentrations (>20 mM), 1 h after administration there
was little difference between IV and IP plasma ascorbate lev-
els (~6 mM). Using BALB/c mice, Yeom et al. (14) showed that
high-dose ascorbate injections (30 mg/mouse ~ 1 g/kg) inhibited
sarcoma 180 tumor growth, and, dependent on time of admin-
istration, could play a preventative or therapeutic role through
reduction of angiogenesis (14). Similarly, continuous high-dose
IP injections (4 g/kg) produced a reduction in hormone-refractory
prostate tumor volume and a decrease in metastatic lesions of over
50% (15). Furthermore, tumor growth of Lewis lung carcinomas
and metastatic spread were reduced using a combination of IP
vitamin C and vitamin K (16).
The maximum plasma levels achieved following injection with
high-dose ascorbate in patients are about 100-fold higher than
those achievable via dietary intake (17). Similarly, oral dosing in
mice (6 g/L) did not reach pharmacological plasma levels (13).
Combined treatment of ascorbate with vitamin K at dietary levels
increased murine lifespan by 45% (18) and reduced metastasis in
a liver cancer model (19). However, as ascorbate was not tested
separately, its contribution is unclear.
From these reports, there appears to be an anti-tumor effect at
high-dose ascorbate in wild type mice bearing syngeneic tumors.
IMMUNE-COMPROMISED MICE WITH HUMAN TUMOR XENOGRAFTS
The nude (Nu/Nu) mouse (20, 21) has been used in oncology for
decades to characterize the growth, spread, and drug responses
of human tumors (xenografts). This mouse strain has a mutation
on chromosome 11 (Foxn1nu-), resulting in an absent thymus
and greatly reduced number of T-cells, yet is able to mount
a limited immune response (22–24). Human pancreatic tumor
xenografts in nude mice treated with pharmacological levels of
ascorbate (4 g/kg daily) were significantly smaller than untreated
controls (7) and, using the same dosage, tumor volume of human
ovarian, pancreatic, and glioblastoma models was significantly
reduced (>40%) (25, 26). Similarly, daily IP injections of lower
doses of ascorbate (0.15 g/kg) were associated with a reduction in
tumor growth of human colorectal cancer xenografts (WiDr) (27),
although this study was limited by small numbers per treatment
group (n= 5). Human erythromyeloid leukemia tumors (K562),
grown in nude mice, showed a 60% reduction in size compared
to controls 4 weeks after a single IP injection of a combination of
ascorbate/menadione (1 g/kg and 10 mg/kg, respectively) (28).
Severe combined immune deficiency (SCID) mice carry a
mutation on chromosome 16 (DNA repair enzyme Prkdc−) and
have lost the ability to produce B- and T-cells. However, these
mice still contain low number of leukocytes and produce nor-
mal numbers of natural killer cells (29). Importantly, this mouse
strain is unable to fight infections or reject tumors, and is, there-
fore, used widely in drug development studies using human tumor
xenografts. When SCID mice were supplemented with ascorbate
(5 g/L) in their drinking water, growth of human lymphoma
xenografts was reduced, and this was attributed to an associated
reduction in the transcription factor HIF-1 (30). In contrast, a
study using prostate xenografts grown in SCID mice showed that
PO (40 mg/kg or 500 mg/kg) administration of ascorbate was not
sufficient to reduce tumor growth (31). Pharmacokinetic analysis
conducted in this study indicated that plasma levels were elevated
and maintained for at least 6 h (31), which is different to previous
reports (13).
In summary, data from immune-compromised mice indicate
an anti-tumor effect with high-dose ascorbate, dependent on dose
and route of administration (Table 1).
CARCINOGEN-INDUCED TUMORS IN ASCORBATE-SYNTHESIZING
ANIMALS
The potential role of ascorbate in the prevention of carcinogenesis
has been investigated for many years, and recent studies are sum-
marized here. The effect of dietary ascorbate on oestrogen-induced
breast carcinogenesis was investigated in August Copenhagen Irish
(ACI) rats (35). Ascorbate attenuated oestrogen-induced alter-
ations in oxidative stress markers and enzyme activity, and reduced
incidence of neoplastic lesions. In contrast, in some strains of rats,
ascorbate increased carcinogen-induced bladder carcinoma (N -
butyl-N -(4-hydroxybutyl)-nitrosamine), but in others it made
no difference (36, 37). Similarly, in SKH-1 hairless mice exposed
to genotoxic UV light, dietary ascorbate increased pre-cancerous
and malignant skin lesions (38). The impact of ascorbate on
carcinogenesis, therefore, remains unresolved.
In summary, few studies measured plasma levels and none mea-
sured tumor ascorbate levels, which is a vital starting point for
mechanistic studies. Studies were difficult to compare, due to dif-
ferent doses and administration routes of ascorbate (Table 1).
Most studies investigated high-dose ascorbate, and no clear
molecular mechanisms were reported.
ASCORBATE-DEPENDENT ANIMALS
A number of early studies investigated ascorbate levels and tumor
progression in the naturally deficient rodent, the guinea pig (39–
41). In guinea pigs, ascorbate was reportedly preferentially taken
up in tumor tissue (Dael and Biltris sarcoma) following IV injec-
tion of 50 mg ascorbate (42). Intermittent scurvy increased the fre-
quency of carcinogen-induced tumors compared to healthy guinea
pigs (43). In contrast, another study showed that increased ascor-
bate supplementation was associated with more rapidly growing
tumors (41). In this study, guinea pigs, maintained on a scorbutic
diet (0.3 mg/kg/day), showed increased tumor regression com-
pared to animals maintained on higher doses (10 mg/kg/day or
1 g/kg/day), suggesting that tumors required ascorbate for growth.
More recently, injection of ascorbate (500 mg/kg/day SC) or oral
supplementation were shown to inhibited tumor growth in guinea
pigs (44). Tumor growth was inversely correlated with tumor
ascorbate levels, and when tumor ascorbate exceeded 1 mM, tumor
growth was inhibited in >50% of animals. Thus, conflicts in the
guinea pig data remain unresolved.
Improvements in genetic modifications have led to the pro-
duction of a range of specific mouse models to study the role
of ascorbate (Table 2). These genetically modified models con-
tain deficiencies in ascorbate transporters and deficiencies in key
points of the biosynthetic pathway.
MICE DEFICIENT IN GULONOLACTONE OXIDASE
Gulo–/– mice are genetically modified C57BL/6 mice, which con-
tain deletions in exons 3 and 4 of l-gulonolactone oxidase, ren-
dering the enzyme inactive, and resulting in animals that require
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daily ascorbate supplementation, similar to human beings (45).
As these animals have fully functional immune systems, they grow
only syngeneic murine tumors.
Supplemented Gulo–/– mice (500 ppm l-ascorbyl-2-
polyphosphate with 150 mg/L ascorbate in drinking water)
implanted with either 4TI breast tumors or B16F0 melanoma cells,
showed reduced tumor growth and metastases compared with un-
supplemented mice (50). Un-supplemented mice had ascorbate
completely withdrawn for 4 weeks prior to tumor implantation,
which has previously been shown to result in undetectable levels
of ascorbate in plasma and most tissues, a significant reduction
in mouse weight, and classical symptoms of scurvy and severe ill
health (51). Using an ovarian tumor model, Kim et al. (52) showed
that supplementation with oral ascorbate (1 g/L) reduced tumor
growth and prolonged the onset of disease progression in tumor
bearing Gulo–/– mice, again in comparison to un-supplemented
mice (52). Conflicting data were reported by Telang et al. (53),
who showed that ascorbate depletion resulted in restricted tumor
growth of Lewis lung carcinoma via restriction of angiogenesis,
suggesting that a reduction of ascorbate may be a therapeutic
approach (53).
Ascorbate uptake has been investigated in Gulo–/– mice (54, 55).
Depletion of ascorbate led to enhanced expression of the SVCT
transporters in the liver, small intestine, and cerebellum, with
an associated increase in ascorbate uptake in isolated hepatocytes
from Gulo–/– mice compared with wild type mice (54, 55).
“Spontaneous fracture” or “Sfx” mice are an inbred strain in a
BALB/c genomic background. These mice were first described to
contain an autosomaly recessive mutation, in which litter mates
were phenotypically identical until ~6 weeks old when body mass,
bone, and metabolic function decreased (47). The sfx gene has
since been located to chromosome 14 and it is now known to con-
tain the deletion of all 12 exons in the gene for l-gulonolactone
oxidase (46). The Sfx mice require daily supplementation with
adequate ascorbate to prevent scurvy, similar to the C57BL/6
Gulo–/– mice. An inverse relationship between the level of ascor-
bate supplementation and tumor weight of B16F0 tumors was
demonstrated in this model (56). In contrast, Parsons et al. (57)
found no difference between ascorbate depleted mice and controls
in respect to mammary tumor growth (57).
All above studies compared fully supplemented Gulo–/– mice
with severely scorbutic animals, which is likely to confound
conclusions regarding the impact of ascorbate on cancer.
MICE DEFICIENT IN ASCORBATE TRANSPORTERS
Ascorbate is transported by two mechanisms, either by direct
transport (sodium-dependent vitamin C transporters SVCT1 and
2), or by the uptake of dehydroascorbic acid (DHA) via glucose
transporters, and subsequent intracellular reduction to ascor-
bate. SVCT1 is expressed on epithelial tissues such as intestine
and kidney, where it contributes to the supply and maintenance
of whole-body ascorbate levels, whereas expression of SVCT2 is
more widespread, and governs the cellular concentration of ascor-
bate (58). A recent study in BALB/C mice bearing breast cancer
xenografts analyzed the effect in vivo of manipulating tumor
SVCT2 levels (59). It demonstrated that an increase of SVCT2
levels was associated with increased tumor growth delay following
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Table 2 | Current ascorbate deficient murine models.
Model Description Model type Reference
GULO−/− Deletions in the exons 3 and 4 rendering the GULO gene inactive. GM (45)
SFX mouse Deletions in all 12 exons in the GULO gene. Spontaneous (46, 47)
SVCT1–/– Exons 1–12 of the Slc23a1 gene replaced by NeoR. SLC23A1– shown to have significant reductions in
renal reabsorption.
GM (48)
SVCT2–/– Deletion of 592 nucleotides causing mRNA frameshift. Deficiency of the transporter is lethal in
neonates.
GM (49)
GRKO/ARKO−/− Double KO model in aldehyde reductase and aldose reductase. 95% reduction in ascorbate synthesis. GM (2)
GULO, gulonolactone oxidase; KO, knockout; GM, genetically modified; SVCT, sodium-dependant vitamin C transporter.
daily IP ascorbate injections (1 g/kg), and a reduction of SVCT2
was associated with a reduction in tumor response (59). These
results indicate that intracellular ascorbate concentrations play a
major role in tumor response to high-dose vitamin C treatment.
Although SVCT-knockout mice have been created (48, 49), they
have not yet been used in cancer research. There is evidence that
mice and rats have reduced (SVCT-dependent) ascorbate trans-
port compared to human beings and guinea pigs (51, 60, 61). This
will affect studies on ascorbate transport and metabolism in those
animals, but should not impact on research into cancer if plasma
and tissue levels are monitored.
MICE DEFICIENT IN ALDEHYDE REDUCTASE AND ALDOSE REDUCTASE
Recently, the aldehyde reductase (GR) and aldose reductase (AR)
double knockout (GRKO/ARKO) mouse has been established on
a C57BL/6 background (2). This model silences key enzymes in
the ascorbate biosynthetic pathway, leading to a 95% reduction in
liver synthesis of ascorbate. Similar to Gulo–/– mice, these animals
will become scorbutic without supplementation. This model has
not yet been used in cancer research.
POTENTIAL MECHANISMS IN CANCER
There is sparse evidence for the role of ascorbate in the tumor
microenvironment, and factors likely to influence tumor response
include species, tumor type, size at treatment, whether tumors
were grown subcutaneously or orthotopically, ascorbate trans-
porter status, and vascularization, which have all not been rig-
orously investigated. With the exception of early data in guinea
pigs (42), few studies have reported plasma levels and none have
investigated tumor ascorbate levels. As tumor ascorbate follow-
ing intervention in neither human beings nor mice has ever been
measured, the optimal dose for maximum tumor concentrations
is unknown. A fundamental issue of ascorbate and cancer therapy
is the lack of robust data for ascorbate’s roles in vivo. Pharmacolog-
ical versus physiological levels of ascorbate will have significantly
different effects.
At pharmacological levels, ascorbate may mediate an anti-
tumor effect via apoptosis (32, 62), ATP depletion (26, 63), or
autophagy (7). High doses of ascorbate are believed to act as
prodrug in tissue culture to generate H2O2 and induce cell kill
(64). Chen and colleagues (26, 63), have shown that pharmaco-
logical levels of ascorbate can induce a pro-oxidant state through
H2O2 production, which may lead to ATP depletion. Du et al. (7)
have shown that increased ascorbate concentrations stimulated
an apoptotic response and, at pharmacological levels of ascor-
bate, autophagy, consistent with previously published work (65).
However, these conclusions were drawn from in vitro studies, and
although in vivo work was carried out using the same cell line
(MIA Pac-2), the mechanism was inferred and no biomarkers of
oxidation were measured.
Pharmacological doses have been used without increased liver
toxicity in mice (14, 26), and these doses have been shown to
potentiate the cytotoxtic effect of some chemotherapeutic drugs
in mice (28, 66, 67), whilst offering cardioprotection from the
cytotoxic side effects (68–70). One notable exception was reported
by Heaney et al. (71), who demonstrated a reduction in efficacy
of a range of chemotherapeutic agents when given in combi-
nation with DHA (71). DHA, the oxidized form of ascorbate,
circulates at low levels in vivo of about 2–10µM compared with
50–70µM of ascorbate, and is thus unlikely to play a major
role (72).
At physiological levels, the role of ascorbate in the control of
HIF-1 is the most investigated and plausible pathway to date.
In vitro cell culture and enzyme studies have provided robust
mechanistic data of the role of ascorbate as co-factor for the
oxygen-sensing HIF hydroxylases (5, 73–75), although this has
been refuted (76). In all other studies, increasing ascorbate lev-
els were associated with reduced HIF-1 levels in vitro (10) and
in vivo (30). In addition, levels of two targets of HIF-1, the metallo-
enzymes MMP-2 and 9, were significantly reduced in the presence
of increased ascorbate (16).
However, all current in vivo data are based either on high-
dose treatment in ascorbate-synthesizing mice (25, 26, 30) or
dietary interventions in ascorbate-dependent animals, but com-
paring healthy and scorbutic mice (50, 53), and may, therefore, not
be relevant for human beings. As tumor levels have not system-
atically been measured following high-dose ascorbate treatment
in these mouse studies, it is unclear whether pharmacological,
toxic levels were achieved, thus accounting for an anti-tumor effect
via the proposed production of H2O2. Or, alternatively, whether
these high doses were required to overcome the poor vasculariza-
tion characteristic of solid tumors, thus achieving physiological
concentrations and regulating factors such as HIF-1 via ascor-
bate’s co-factor role. Levels and function of ascorbate transporters,
SVCT1 and SVCT2, in tumor tissue have only recently started to be
investigated (59), and differences between species will affect tissue
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levels (61). The other potential roles of ascorbate during cancer
growth, such as epigenetic changes and immune function, have
also not been investigated.
CONCLUSION
Ascorbate could be an inexpensive addition to standard can-
cer treatment if proven effective. Current animal models have
provided evidence of, and some mechanistic insight into, the
anti-tumor effects of ascorbate. However, the limited use of suit-
able ascorbate dependent, yet non-scorbutic, models has limited
the strength of the evidence. In addition to using ascorbate-
synthesizing animals, many studies are weakened by using a wide
range of doses and administration routes that are inconsistent
among studies, and seldom measure circulating or tissue ascor-
bate levels. The role of species-specific gene regulation of ascorbate
synthesis and transport may further complicate translation from
animals into patients. Hence, carefully conducted, clinically rele-
vant, pre-clinical studies are still required to convince a generally
sceptical medical audience of the potential worth of ascorbate as
an adjunct to therapy.
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